Category: imidazoles-derivatives

Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study was written by Costes-Tertrais, Domitille;Hueso, Thomas;Gastinne, Thomas;Thieblemont, Catherine;Oberic, Lucie;Bouabdallah, Krimo;Garciaz, Sylvain;Tchernonog, Emmanuelle;Dartigeas, Caroline;Ribrag, Vincent;Fogarty, Patrick;Casasnovas, Rene-Olivier;Houot, Roch;Delette, Caroline;Malak, Sandra;Fornecker, Luc-Matthieu;Gressin, Remy;Damaj, Gandhi;Le Gouill, Steven. And the article was included in Bone Marrow Transplantation in 2022.Electric Literature of C16H21Cl2N3O2 The following contents are mentioned in the article:

Cytarabine-based immuno-chemotherapy followed by autologous stem cell transplantation (ASCT) consolidation is standard of care for fit patients with Mantle Cell Lymphoma (MCL). BEAM (Carmustine, Etoposide, Aracytine, Melphalan) is among the most frequently used conditioning regimen. Studies comparing BEAM with Bendamustine-EAM (BeEAM) have suggested that patients treated with BeEAM have a better progression-free survival (PFS). We performed a cross-study anal. to better evaluate BeEAM. Thirty-five patients from a retrospective study who received R-DHAP/BeEAM were compared to 245 patients from the LyMa trial (NCT00921414) who all received R-DHAP followed by R-BEAM. PFS and Overall Survival (OS) were estimated using Kaplan-Meier methods. At 2 years there was no difference between R-BEAM and BeEAM in either PFS (84.9% vs. 87.9%; p = 0.95) or OS (91.8% vs. 94.2%; p = 0.30). Analyses were repeated on a propensity score to reduce biases. Each patient from the BeEAM cohort (n = 30) was matched to three patients from the R-BEAM cohort (n = 90) for age, sex, MIPI score, pre-transplant status disease and rituximab maintenance (RM). PFS and OS at 2 years remained similar between R-BEAM and BeEAM with more renal toxicity in BeEAM group. MCL patients who received R-DHAP induction before ASCT have similar outcome after R-BEAM or BeEAM conditioning regimen. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Electric Literature of C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Electric Literature of C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial was written by Kumar, Sudhir;Sharma, Atul;Malik, Prabhat Singh;Gogia, Ajay;Pathak, Neha;Sahoo, Ranjit Kumar;Gupta, Ritu;Prasad, Chandra Prakash;Kumar, Lalit. And the article was included in British Journal of Haematology in 2022.Safety of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

Treatment of patients with resistant/refractory multiple myeloma (MM) is an unmet need. In this phase II study, author evaluated the role of bendamustine, pomalidomide and dexamethasone combination in this setting. Between Feb. 2020 and Dec. 2021, 28 patients were recruited. Patients received bendamustine 120 mg/m²day 1, pomalidomide 3 mg days 1-21, and dexamethasone 40 mg days 1, 8, 11, 22, regimen given for a maximum of six cycles. The median (range) age of the patients was 54 (30-76) years and 15 (53.6%) were males. Patients had received a median (range) of three (two-six) prior lines and 85.7% were refractory to both lenalidomide and bortezomib. The primary end-point was the overall response rate (ORR) defined as 鈮artial response after at least three cycles. Secondary objectives were toxicity, progression-free survival (PFS), time to progression and overall survival (OS). An intent-to-treat anal. was done. An ORR of 57.6% was achieved. Patients with extramedullary myeloma had a better response rate. At a median follow-up of 8.6 mo, the median PFS and OS were 6.2 and 9.7 mo resp. Toxicity was manageable; mainly haematol. (neutropenia, 46.4%; anemia, 42.8%; and thrombocytopenia, 7.1%). Bendamustine, pomalidomide and dexamethasone could be a novel combination for the heavily pretreated, lenalidomide-refractory myeloma population. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Safety of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Safety of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

A turn-on luminescent probe for Fe³⁺ and ascorbic acid with logic gate operation based on a zinc(II)-based metal-organic framework was written by Tang, Jing;Feng, Doudou;Yang, Jie;Ma, Xuehui;Wang, Xiao-Qing. And the article was included in New Journal of Chemistry in 2020.SDS of cas: 1374155-84-6 The following contents are mentioned in the article:

A 2D zinc(II)-based metal-organic framework (Zn-MOF) formulated as [Zn(bimpy)(1,4-ndc)]路H₂O (1, bimpy = 3,5-bis(1-imidazolyl)pyridine and 1,4-ndc = 1,4-naphthalenedicarboxylic acid) was synthesized by solvothermal reaction. Complex 1 exhibits high water and pH-independent stability. It can detect Fe³⁺ and ascorbic acid (AA) as a “turn-off” fluorescence probe and a “turn-on” fluorescence probe in aqueous solution with high sensitivity and selectivity, resp. The detection limits of 1 for Fe³⁺ and AA are about 8.82 x 10^-7 M and 6.12 x 10^-7 M, resp. The fluorescence intensity of the Fe³⁺@1 system can be obviously recovered after adding AA due to the reduction of Fe³⁺, which exhibits a fluorescence “turn-on” signal (turn-off-on) for Fe³⁺@1 toward AA with a low detection limit (3.53 x 10^-7 M). Complex 1 still exhibits good detection of Fe³⁺ and AA after washing and using for five cycles. Addnl., two different multi-input mol. logic gates are established. One is used to distinguish the effect of Fe³⁺ and Fe²⁺ on the fluorescence of complex 1, and the other is to further explain the regulation of Fe³⁺ and AA on the fluorescence of complex 1. This work shows that complex 1 is the first MOF-based “turn-on” fluorescent probe for both Fe³⁺ and AA in aqueous solution This study involved multiple reactions and reactants, such as 3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6SDS of cas: 1374155-84-6).

3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.SDS of cas: 1374155-84-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Comparative characteristics of proton pump inhibitor effectiveness in the treatment of gastric ulcer and duodenal ulcer was written by Balitska, Olesya P.;Germanyuk, Tamara A.;Hryhoruk, Yuliia M.;Ivko, Tatiana I.;Tomashevska, Yuliia O.;Koval, Vasyl M.;Polishchuk, Yuliia M.;Hutsol, Viktoriia V.;Artemchuk, Myhailo A.. And the article was included in Current Issues in Pharmacy and Medical Sciences in 2020.Synthetic Route of C18H20N3NaO3S The following contents are mentioned in the article:

Materials and methods: The materials of this research are the results of 86 original studies on the effectiveness of proton pump inhibitors anal. Methods. Descriptive, statistical, retrospective. Results and Conclusion. According to the clin. random researches, Omeprazole preparations are not included in the list due to proven better effectiveness of Esomeprazole drugs. Moreover, lansoprazole drugs are not included according to proven short-acid inhibitory effect. In addition, the brand of mentioned above preparation does not exist on the pharmaceutical market of Ukraine. Furthermore, rabeprazole preparations are presented in the research by Pariet (brand) and by the effective generic Barol, while pantoprazole preparations are represented in the research by Kontrolok (brand) and by the generic Pultset, as well as by Nolpaza. Herein, the Pantosan effect was not significantly different from the effect of Pultset and Nolpaza, but the preparation is much more expensive. In terms of efficiency (%), 4 wk repair of mucosal defects was carried out by way of the following treatment regimens: Barol + Amoxicillin + Clarythromycin (90.9卤6.2), Pariet + Amoxicillin + Clarythromycin (83卤2.6), Kontrolok + Amoxicillin + Clarythromycin (100卤1.3), Pultset + Amoxicillin + Clarythromycin (88卤4.1), Nolpaza + Amoxicillin + Clarythromycin (72卤4.1), Ezolonh + Amoxicillin + Clarythromycin (87.7卤3.8), Neksium + Amoxicillin + Clarythromycin (96.1卤3.1). This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Synthetic Route of C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Synthetic Route of C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole was written by Ochoa, Dolores;Roman, Manuel;Cabaleiro, Teresa;Saiz-Rodriguez, Miriam;Mejia, Gina;Abad-Santos, Francisco. And the article was included in BMC Pharmacology and Toxicology in 2020.Quality Control of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:

We aimed to evaluate the effect of food on the pharmacokinetics of omeprazole, rabeprazole, and pantoprazole. Setting: The study population comprised 186 healthy volunteers participating in 6 bioequivalence clin. trials. Method: Subjects were evaluated to determine the effect of a high-fat breakfast on the pharmacokinetics of omeprazole (n = 36), rabeprazole (n = 69), and pantoprazole (n = 81). Main outcome measure: Drug plasma concentrations were measured using high-performance liquid chromatog. coupled to mass spectrometry. Results: Food affected the pharmacokinetics of omeprazole (increased T_max and decreased AUC and C_max), pantoprazole (increased T_max and decreased AUC), and rabeprazole (increased T_max, C_max and half-life). Food increased variability in T_max for all 3 drugs, delaying absorption around 3 to 4 h and until 20 h in some subjects. Conclusion: As food delays the absorption of PPIs and increases their variability, it would be better to administer these drugs under fasting conditions. Trial registration: European Union Drug Regulating Authorities Clin. Trials Database: EudraCT: 2004-003863-59 (registration date 05/MAR/2004), EudraCT 2006-001162-17 (registration date 17-MAR-2006), EudraCT: 2007-002489-37 (registration date 12-JUN-2007), EudraCT: 2007-002490-31 (registration date 12-JUN-2007), EudraCT: 2010-024029-19 (registration date 23-NOV-2010). This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Quality Control of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Quality Control of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Pantoprazole, a proton-pump inhibitor, impairs human sperm motility and capacitation in vitro was written by Escoffier, Jessica;Arnaud, Bastien;Kaba, Mayis;Hograindleur, Jean Pascal;Le Blevec, Emilie;Martinez, Guillaume;Stevant, Isabelle;Ray, Pierre F.;Arnoult, Christophe;Nef, Serge. And the article was included in Andrology in 2020.Formula: C18H20N3NaO3S The following contents are mentioned in the article:

Background : The effects of PPIs on human sperm fertilizing capacity were poorly investigated although these drugs are widely over-used. Objectives : Do PPIs, which are among the most widely sold drug in the word, impact neg. human sperm capacitation and sperm motility Materials and methods : The effects of PPIs on human sperm maturation and motility were analyzed by CASA, flow cytometry, and Western blot. Results : We tested the impact of 6 different PPIs on human sperm motility and capacitation. We showed that pantoprazole, but not the other PPIs, decreased sperm progressive motility and capacitation-induced sperm hyperactivation. We therefore investigated further the effects of pantoprazole on sperm capacitation, and we observed that it had a significant deleterious effect on the capacitation-induced hyperpolarization of the membrane potential and capacitation-associated protein phosphorylation. Discussion and Conclusion : Our results indicate that exposure to pantoprazole has an adverse effect on the physiol. competence of human spermatozoa. As the capacitation process takes place within the female tract, our results suggest that PPIs intake by the female partner may impair in vivo sperm maturation and possibly fertilization. Moreover, the absence of adverse effect by PPIs on mouse sperm emphasizes the need to develop reprotox assays using human material to better assess the effects of medication intake on sperm physiol. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Formula: C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Formula: C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

First characterization of a microsporidial triosephosphate isomerase and the biochemical mechanisms of its inactivation to propose a new druggable target was written by Garcia-Torres, Itzhel;De la Mora-De la Mora, Ignacio;Hernandez-Alcantara, Gloria;Molina-Ortiz, Dora;Caballero-Salazar, Silvia;Olivos-Garcia, Alfonso;Nava, Gabriela;Lopez-Velazquez, Gabriel;Enriquez-Flores, Sergio. And the article was included in Scientific Reports in 2018.Safety of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:

The microsporidia are a large group of intracellular parasites with a broad range of hosts, including humans. Encephalitozoon intestinalis is the second microsporidia species most frequently associated with gastrointestinal disease in humans, especially immunocompromised or immunosuppressed individuals, including children and the elderly. The prevalence reported worldwide in these groups ranges from 0 to 60%. Currently, albendazole is most commonly used to treat microsporidiosis caused by Encephalitozoon species. However, the results of treatment are variable, and relapse can occur. Consequently, efforts are being directed toward identifying more effective drugs for treating microsporidiosis, and the study of new mol. targets appears promising. These parasites lack mitochondria, and oxidative phosphorylation therefore does not occur, which suggests the enzymes involved in glycolysis as potential drug targets. Here, we have for the first time characterized the glycolytic enzyme triosephosphate isomerase of E. intestinalis at the functional and structural levels. Our results demonstrate the mechanisms of inactivation of this enzyme by thiol-reactive compounds The most striking result of this study is the demonstration that established safe drugs such as omeprazole, rabeprazole and sulbutiamine can effectively inactivate this microsporidial enzyme and might be considered as potential drugs for treating this important disease. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Safety of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.Safety of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Rate of major bleeding with ibrutinib versus bendamustine-rituximab in chronic lymphocytic leukemia: A population-based cohort study was written by Dhopeshwarkar, Neil;Yang, Wei;Hennessy, Sean;Rhodes, Joanna M.;Cuker, Adam;Leonard, Charles E.. And the article was included in American Journal of Hematology in 2022.Synthetic Route of C16H21Cl2N3O2 The following contents are mentioned in the article:

The approval of ibrutinib, a Bruton’s Tyrosine Kinase (BTK) inhibitor, has revolutionized the treatment landscape for treatment-naive and relapsed or refractory chronic lymphocytic leukemia (CLL) patients. However, bleeding was frequently observed in ibrutinib-treated patients and has become a notable safety concern. Major bleeding, however, was uncommonly observed in clin. trials, with incidences ranging from 2%-8%. Herein authors compare incidence rates of real-world major and clin.-relevant bleeding between ibrutinib- and bendamustine-rituximab (BR)-treated individuals diagnosed with CLL. The primary outcome was major bleeding, defined as bleeding resulting in inpatient hospitalization. The secondary outcome was clin.-relevant bleeding, which was a composite of bleeding events resulting in inpatient hospitalization (i.e., major bleeding) and those resulting in emergency department presentation. This study found that, though the rate of major bleeding with ibrutinib in a real-world population was comparable to clin. trial populations, an increased rate of clin.-relevant bleeding compared to BR is evident. As the use of 2nd-generation BTK inhibitors increases, clinicians will require information on the real-world risks with individual agents within the therapy class. This study will help serve as a benchmark for ibrutinib-related bleeding until such post-market studies among all available BTK inhibitors can be conducted. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Synthetic Route of C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Synthetic Route of C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Predictive model of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension was written by Yorifuji, Kennosuke;Uemura, Yuko;Horibata, Shinji;Tsuji, Goh;Suzuki, Yoko;Nakayama, Kazuhiko;Hatae, Takashi;Kumagai, Shunichi;Emoto, Noriaki. And the article was included in Canadian Journal of Physiology and Pharmacology in 2020.Category: imidazoles-derivatives The following contents are mentioned in the article:

Bosentan, an endothelin receptor antagonist, has been widely used as a first-line medication for the treatment of pulmonary arterial hypertension (PAH). It has been shown to improve symptoms of hypertension, exercise capacity, and hemodynamics and prolong time to clin. worsening. However, liver dysfunction is a major side effect of bosentan treatment that could hamper the optimal management of patients with PAH. Previously, we demonstrated, using drug metabolism enzymes and transporters anal., that the carbohydrate sulfotransferase 3 (CHST3) and CHST13 alleles are significantly more frequent in patients with elevated aminotransferases during therapy with bosentan than they are in patients without liver toxicity. In addition, we constructed a pharmacogenomics model to predict bosentan-induced liver injury in patients with PAH using two single-nucleotide polymorphisms and two nongenetic factors. The purpose of the present study was to externally validate the predictive model of bosentan-induced liver toxicity in Japanese patients. We evaluated five cases of patients treated with bosentan, and one presented with liver dysfunction. We applied mutation alleles of CHST3 and CHST13, serum creatinine, and age to our model to predict liver dysfunction. The sensitivity and specificity were calculated as 100% and 50%, resp. Considering that PAH is a rare disease, multicenter collaboration would be necessary to validate our model. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Category: imidazoles-derivatives).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3鈥揅6) is higher than in water and generally decreases with a Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Category: imidazoles-derivatives

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

A novel copper(I) metal-organic framework as a highly efficient and ultrasensitive electrochemical platform for detection of Hg(II) ions in aqueous solution was written by Wang, Xiao-Qing;Tang, Jing;Ma, Xuehui;Wu, Dan;Yang, Jie. And the article was included in CrystEngComm in 2021.Name: 3,5-Di(1H-imidazol-1-yl)pyridine The following contents are mentioned in the article:

The selective detection of toxic Hg(II) ions is of great significance for industrial processing and environmental remediation. Herein, a novel copper(I) metal-organic framework [Cu₃Cl₃(bimpy)₃] (1) (bimpy = 3,5-bis(1-imidazolyl)pyridine) was constructed by a solvothermal method. Single-crystal X-ray anal. shows that complex 1 is a 2-fold interpenetrated three-dimensional structure with a tfj topol., exhibiting high thermal stability and water stability. Complex 1 was used to modify a glassy carbon electrode (GCE) for the determination of Hg(II) in 0.1 M phosphate buffer solution (PBS) at pH = 7.0. However, on account of the poor electron-conductive property of complex 1, acetylene black (AB) was introduced into complex 1 to improve its electrochem. sensing activity. The electrochem. sensing property of AB and the complex 1 modified GCE was investigated by cyclic voltammetry and chronoamperometric tests. Under the optimal conditions, AB/complex 1/GCE exhibits a high sensitivity of 16.85 渭A 渭M^-1 cm^-2 and a low limit of detection of 1.01 nM in the wide linear range from 2.0 渭M to 64 渭M. AB/complex 1/GCE could also be applied for detecting Hg(II) ions in tap water and river water. The aptasensor provides a valuable tool with satisfactory anti-interference, reproducibility, repeatability, simple preparation, and satisfactory applicability for the sensing of Hg(II) ions. This study involved multiple reactions and reactants, such as 3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6Name: 3,5-Di(1H-imidazol-1-yl)pyridine).

3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3鈥揅6) is higher than in water and generally decreases with a Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Name: 3,5-Di(1H-imidazol-1-yl)pyridine

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem